Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

13.0%

3 terminated out of 23 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

9%

2 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed with results

Key Signals

1 with results67% success

Data Visualizations

Phase Distribution

21Total
Not Applicable (12)
P 1 (4)
P 2 (3)
P 4 (2)

Trial Status

Recruiting8
Completed6
Unknown3
Terminated3
Not Yet Recruiting1
Suspended1

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT07286149Phase 1RecruitingPrimary

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

NCT06788912Phase 2RecruitingPrimary

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

NCT05731076Not ApplicableActive Not Recruiting

Self-Management Support for Lung Cancer Patients With Cachexia

NCT07543601Not ApplicableRecruiting

Enhanced COPD Management in Suspected Lung Cancer Patients

NCT06440616Not ApplicableRecruitingPrimary

Benefit of Spectral Information in Patients Suspected for Lung Cancer

NCT07071103Phase 2Recruiting

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

NCT05013554Phase 1Terminated

Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

NCT05890872Not ApplicableCompletedPrimary

Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer

NCT06079970Not ApplicableRecruiting

Confocal Laser Endomicroscopy VERification

NCT05241873Phase 1TerminatedPrimary

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

NCT04973293Not ApplicableRecruitingPrimary

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

NCT05974475RecruitingPrimary

MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer

NCT06530667Not ApplicableNot Yet RecruitingPrimary

Broadband Collaborative Pulse Ablation Instrument Treating Malignant Pulmonary Nodules

NCT03352245Not ApplicableCompletedPrimary

Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer

NCT05404022Not ApplicableCompletedPrimary

Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years

NCT04036721Phase 4SuspendedPrimary

Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis

NCT04059887Phase 4CompletedPrimary

Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]

NCT03834116Not ApplicableCompletedPrimary

Resistance Inspiratory Muscle Training for Patients With Thoracic Malignancies

NCT05414188Not ApplicableUnknownPrimary

Beneficial Effect of Pulmonary Rehabilitation in Lung Cancer Patients Receiving Radiation Therapy

NCT03824977CompletedPrimary

Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery

Scroll to load more

Research Network

Activity Timeline